Skip to main content

Advertisement

SpringerLink
Log in

Optimal Therapies for Newly Diagnosed Elderly Patients with Glioblastoma

  • Neuro-oncology (GJ Lesser, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Newly diagnosed elderly patients (age > 65–70 years) with glioblastoma should be treated with a patient-centred approach by a multi-disciplinary team. Chronological age alone should not be considered as a contraindication to treatment with maximal safe surgical resection. A 3-week course of adjuvant radiation and chemotherapy is appropriate in selected elderly patients with favourable Karnofsky performance status (KPS) who cannot tolerate a longer 6-week course of fractionated radiotherapy. The presence or absence of 06-methylguanine-DNA methyltransferase (MGMT) promoter methylation can be used to guide clinical decision-making as both prognostic and predictive biomarkers. This review provides an update and summary of the available evidence for treating newly diagnosed elderly patients with glioblastoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. Central Brain Tumor Registry of the United States (CBTRUS) statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro-Oncology. 2015;17(suppl 4):1–62. https://doi.org/10.1093/neuonc/nov189.

    Article  Google Scholar 

  2. Arvold ND, Reardon DA. Treatment options and outcomes for glioblastoma in the elderly patient. Clin Interv Aging. 2014;9:357–67. https://doi.org/10.2147/CIA.S44259.

    PubMed  PubMed Central  Google Scholar 

  3. Iwamoto FM, Reiner AS, Panageas KS, Elkin EB, Abrey LE. Patterns of care in elderly glioblastoma patients. Ann Neurol. 2008;64:628–34. https://doi.org/10.1002/ana.21521.

    Article  PubMed  Google Scholar 

  4. Tsang DS, Khan L, Perry JR, Soliman H, Sahgal A, Keith JL, et al. Survival outcomes in elderly patients with glioblastoma. Clin Oncol (R Coll Radiol). 2015;27:176–83. https://doi.org/10.1016/j.clon.2014.11.026.

    Article  CAS  Google Scholar 

  5. Zouaoui S, Amélie D, Fabbro-Peray P, Mathieu-Daudé H, Rigau V, Fabbro M, et al. Oncological patterns of care and outcomes for 265 elderly patients with newly diagnosed glioblastoma in France. Neurosurg Rev. 2014;37:415–24. https://doi.org/10.1007/s10143-014-0528-8.

    Article  PubMed  Google Scholar 

  6. Scott JG, Bauchet L, Fraum TJ, Nayak L, Cooper AR, Chao ST, et al. Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 or older. Cancer. 2012;118(22):5595–600. https://doi.org/10.1002/cncr.27570.

    Article  PubMed  PubMed Central  Google Scholar 

  7. • Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic, randomised, phase 3 trial. Lancet Oncol. 2012;13:916–26. https://doi.org/10.1016/S1470-2045(12)70265-6. A three-arm randomized trial in elderly patients > 60 years with glioblastoma, showing hypofractionated radiotherapy (34 Gy in 10 fractions), and treatment with temozolomide were each associated with a survival benefit when compared to standard radiotherapy.

    Article  PubMed  Google Scholar 

  8. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13:707–15. https://doi.org/10.1016/S1470-2045(12)70164-X.

    Article  CAS  PubMed  Google Scholar 

  9. •• Perry JR, Laperriere N, O’Callaghan CJ, Brandes AA, Menten J, Phillips C, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017;376:1027–37. https://doi.org/10.1056/NEJMoa1611977. A phase III randomized trial in elderly patients aged > 65 years with glioblastoma showing a survival benefit when temozolomide was combined with hypofractionated radiotherapy (40 Gy in 15 fractions) as compared to radiotherapy alone. This benefit was greatest in patients with MGMT promoter methylation.

    Article  CAS  PubMed  Google Scholar 

  10. Balducci L, Colloca G, Cesari M, Gambassi G. Assessment and treatment of elderly patients with cancer. Surg Oncol. 2010;19:117–23. https://doi.org/10.1016/j.suronc.2009.11.008.

    Article  PubMed  Google Scholar 

  11. Vuorinen V, Hinnka S, Farkkila M, Jaaskelainen J. Debulking or biopsy of malignant glioma in elderly people—a randomized study. Acta Neurochir. 2003;145(1):5–10. https://doi.org/10.1007/s00701-002-1030-6.

    Article  CAS  PubMed  Google Scholar 

  12. Roa W, Brasher PMA, Bauman G, Anthes M, Bruera E, Chan A, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22:1583–8. https://doi.org/10.1200/JCO.2004.06.082.

    Article  CAS  PubMed  Google Scholar 

  13. Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356:1527–35. https://doi.org/10.1056/NEJMoa065901.

    Article  CAS  PubMed  Google Scholar 

  14. •WHO. Classification of tumours of the central nervous system; WHO/IARC classification of tumours, 4th Edition Revised, Volume 1. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK,editors. Updated and revised 2016 CNS tumour classification.

  15. Batchelor TT, Betensky RA, Esposito JM, Pham LD, Dorfman MV, Piscatelli N, et al. Age dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res. 2004;10(1 Pt 1):228–33.

    Article  CAS  PubMed  Google Scholar 

  16. von Diemling A, Korshunov A, Hartmann C. The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol. 2011;21:74–87. https://doi.org/10.1111/j.1750-3639.2010.00454.x.

    Article  Google Scholar 

  17. Oberheim Bush NA, Chang SM, Berger MS. Current and future strategies for treatment of glioma. Neurosurg Rev. 2017;40:1–14. https://doi.org/10.1007/s10143-016-0709-8.

    Article  Google Scholar 

  18. Chaichana KL, Garzon-Muvdi T, Parker S, Weingart JD, Olivi A, Bennett R, et al. Supratentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients. Ann Surg Oncol. 2011;18(1):239–45. https://doi.org/10.1245/s10434-010-1242-6.

    Article  PubMed  Google Scholar 

  19. Noorbakhsh A, Tang JA, Marcus LP, McCutcheon B, Gonda D, Schallhorn C, et al. Gross-total resection outcomes in an elderly population with glioblastoma: a SEER-based analysis. J Neurosurg. 2014;120:31–9. https://doi.org/10.3171/2013.9.JNS13877.

    Article  PubMed  Google Scholar 

  20. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96. https://doi.org/10.1056/NEJMoa043330.

    Article  CAS  PubMed  Google Scholar 

  21. Reifenberger G, Hentschel B, Felsberg J, Schackert G, Simon M, Schnell O, et al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer. 2012;131:1342–50. https://doi.org/10.1002/ijc.27385.

    Article  CAS  PubMed  Google Scholar 

  22. Song K, Amatya B, Khan F. Advance care planning in patients with brain tumours: a prospective cohort study. J Cancer Res Ther, Doi. 2015;3(7):85–91. http://dx.doi.org/10.14312/2052-4994.2015-12

  23. Kuchinad KE, Strowd R, Evans A, Riley WA, Smith TJ. J Neuro-Oncol. 2017; https://doi.org/10.1007/s11060-017-2487.

  24. Fritz L, Dirven L, Reijneveld JC, Koekkoek J, Stiggelbout AM, Pasman RW, et al. Advance care planning in glioblastoma patients. Cancers (Basel). 2016;8(11):102. https://doi.org/10.3390/cancers8110102.

    Article  Google Scholar 

  25. Wirsching HG, Tabatabai G, Roelcke U, Hottinger AF, Schmid A, Plasswilm L, et al. Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: efficacy and imaging analyses of the ARTE trial. J Clin Oncol 2017: 35 (suppl; abstr 2014). https://doi.org/10.1200/JCO.2017.35.15.

  26. Stupp R, Taillibert A, Kanner AA, Kesari S, Steinberg DM, Toms SA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015;314(23):2535–43. https://doi.org/10.1001/jama.2015.16669.

    Article  CAS  PubMed  Google Scholar 

  27. Brandes AA, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V, et al. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer. 2009;115:3512–8. https://doi.org/10.1002/cncr.24406.

    Article  CAS  PubMed  Google Scholar 

  28. Laperriere N, Weller M, Stupp R, Perry JR, Brandes AA, Wick W, et al. Optimal management of elderly patients with glioblastoma. Cancer Treat Rev. 2013;39:350–7. https://doi.org/10.1016/j.ctrv.2012.05.008.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

SI and JP are supported by the Crolla Family Chair in Brain Tumour Research.

Author information

Authors and Affiliations

  1. Division of Neurology, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada

    Sarah Ironside MD & James R. Perry MD

  2. Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

    Sarah Ironside MD, Arjun Sahgal MD, Claire Moroney MS, RN(EC) & James R. Perry MD

  3. Division of Neurosurgery, St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada

    Sunit Das MD, PhD

  4. Keenan Research Centre for Biomedical Science of St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada

    Sunit Das MD, PhD

  5. Arthur and Sonia Labatt Brain Tumour Research Centre, University of Toronto, Toronto, ON, Canada

    Sunit Das MD, PhD

  6. Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada

    Arjun Sahgal MD

  7. Division of Neurosurgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada

    Todd Mainprize MD

Authors
  1. Sarah Ironside MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sunit Das MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arjun Sahgal MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Claire Moroney MS, RN(EC)
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Todd Mainprize MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. James R. Perry MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah Ironside MD.

Ethics declarations

Conflict of Interest

Sarah Ironside declares that she has no conflict of interest.

Sunit Das declares that he has no conflict of interest.

Arjun Sahgal reports past educational seminars with Medtronic, Elekta AB, Accuray Inc. and Varian medical systems. He has received research grants from Elekta AB and travel accommodations/expenses from Medtronic, Elekta and Varian and also belongs to the Elekta MR Linac Research Consortium.

Claire Moroney declares that she has no conflict of interest.

Todd Mainprize declares that he has no conflict of interest.

James R. Perry declares that he has no conflict of interest.

Human and Animal Rights

All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki Declaration and its amendments, institutional/national research committee standards and international/national/institutional guidelines).

Additional information

This article is part of the Topical Collection on Neuro-oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ironside, S., Das, S., Sahgal, A. et al. Optimal Therapies for Newly Diagnosed Elderly Patients with Glioblastoma. Curr. Treat. Options in Oncol. 18, 66 (2017). https://doi.org/10.1007/s11864-017-0508-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-017-0508-7

Keywords

Search

Navigation